Cargando…

Distribution of residual tumors in esophageal squamous cell carcinoma after neoadjuvant PD-1 blockade combined with chemotherapy

AIMS: The distribution of residual esophageal squamous cell carcinoma (ESCC) in the esophageal wall and resected lymph nodes was evaluated after neoadjuvant chemoimmunotherapy (nICT). METHODS AND RESULTS: Clinical data were collected from 137 ESCC patients who underwent anti-programmed death 1 thera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Dongxian, Song, Qi, Tang, Han, Shi, Peng, Zhang, Xiaolei, Liu, Yufeng, Wang, Haixing, Deng, Minying, Huang, Jie, Su, Jieakesu, Xu, Chen, Tan, Lijie, Hou, Yingyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012861/ https://www.ncbi.nlm.nih.gov/pubmed/36925921 http://dx.doi.org/10.3389/fonc.2023.1067897

Ejemplares similares

Prognostic value of visual residual tumour cells (VRTC) for patients with esophageal squamous cell carcinomas after neoadjuvant therapy followed by surgery
por: Wang, Xingxing, et al.
Publicado: (2021)

PMS2 Expression With Combination of PD-L1 and TILs for Predicting Survival of Esophageal Squamous Cell Carcinoma
por: Jiang, Dongxian, et al.
Publicado: (2022)

The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma
por: Jiang, Dongxian, et al.
Publicado: (2015)

SOX2 amplification and chromosome 3 gain significantly impact prognosis in esophageal squamous cell carcinoma
por: Wang, Xin, et al.
Publicado: (2021)

Independent prognostic role of PD-L1 expression in patients with esophageal squamous cell carcinoma
por: Jiang, Dongxian, et al.
Publicado: (2016)

Increased MET gene copy number negatively affects the survival of esophageal squamous cell carcinoma patients
por: Wang, Yanqiu, et al.
Publicado: (2019)

Comparison of the prognostic difference between ypTNM and equivalent pTNM stages in esophageal squamous cell carcinoma based on the 8th edition of AJCC classification
por: Jiang, Dongxian, et al.
Publicado: (2020)

Pharmacological Inhibition of PP2A Overcomes Nab-Paclitaxel Resistance by Downregulating MCL1 in Esophageal Squamous Cell Carcinoma (ESCC)
por: Song, Qi, et al.
Publicado: (2021)

Chromosomal and Genomic Variations in Esophageal Squamous Cell Carcinoma: A Review of Technologies, Applications, and Prospections
por: Song, Qi, et al.
Publicado: (2017)

CDK4 Amplification in Esophageal Squamous Cell Carcinoma Associated With Better Patient Outcome
por: Huang, Jie, et al.
Publicado: (2021)

Tumour infiltrating lymphocytes correlate with improved survival in patients with esophageal squamous cell carcinoma
por: Jiang, Dongxian, et al.
Publicado: (2017)

Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma
por: Cheng, Daoan, et al.
Publicado: (2023)

Proteomic analysis reveals key differences between squamous cell carcinomas and adenocarcinomas across multiple tissues
por: Song, Qi, et al.
Publicado: (2022)

The prognostic significance of MCL1 copy number gain in esophageal squamous cell carcinoma
por: Xu, Chen, et al.
Publicado: (2017)

Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma
por: Yang, Guozhen, et al.
Publicado: (2021)

Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
por: Yang, Weixiong, et al.
Publicado: (2022)

The level of macrophage migration inhibitory factor is negatively correlated with the efficacy of PD-1 blockade immunotherapy combined with chemotherapy as a neoadjuvant therapy for esophageal squamous cell carcinoma
por: Wu, Liangliang, et al.
Publicado: (2023)

Identification of clinical prognostic features of esophageal cancer based on m6A regulators
por: Wang, Huimei, et al.
Publicado: (2022)

Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma
por: Wei, Tianhui, et al.
Publicado: (2022)

Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung
por: Feng, Yuan, et al.
Publicado: (2021)

Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial
por: Wang, Hao, et al.
Publicado: (2021)

The Role of Adjuvant Chemotherapy in the Treatment of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemotherapy
por: Li, Keting, et al.
Publicado: (2023)

Stratified treatment of localized cervical esophageal squamous cell carcinoma induced by neoadjuvant immunotherapy plus chemotherapy (SCENIC)
por: Li, Chunguang, et al.
Publicado: (2022)

Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2018)

An alternative high output tissue microarray technique
por: Shi, Yuan, et al.
Publicado: (2013)

Neoadjuvant immunotherapy for resectable esophagal squamous cell carcinoma: An ace up the sleeve
por: Zhou, Qing, et al.
Publicado: (2023)

Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2022)

The success of anti-PD-1 with chemotherapy for esophageal squamous cell carcinoma
por: van Laarhoven, Hanneke W.M., et al.
Publicado: (2023)

Effect of Body Composition Change during Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma
por: Onishi, Sachiyo, et al.
Publicado: (2022)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer
por: Xu, Chen, et al.
Publicado: (2017)

Late stage gastric cancer patients with extra gained HER2 positivity by dual block assessment may not show compromised efficacy to trastuzumab treatment
por: Xu, Chen, et al.
Publicado: (2019)

Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for esophageal squamous cell cancer: A meta-analysis
por: Guo, Yaru, et al.
Publicado: (2022)

Presence of schistosome eggs in lymph node predict unfavorable prognosis in schistosomal colorectal cancer
por: Pan, Weiyu, et al.
Publicado: (2023)

Successful outcome of neoadjuvant PD-1 blockade, VEGFR-2 inhibitor plus chemotherapy for potentially unresectable esophagogastric junctional squamous cell carcinoma: a case report
por: Chen, Kai-Bo, et al.
Publicado: (2022)

Minimally invasive versus open McKeown esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant PD-1 inhibitor plus chemotherapy
por: Chen, Qiuming, et al.
Publicado: (2023)

Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study
por: Zhang, Xuchen, et al.
Publicado: (2023)

Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma
por: Wu, Zhigang, et al.
Publicado: (2021)

Safety and Feasibility of Esophagectomy Following Neoadjuvant Immunotherapy Combined with Chemotherapy for Esophageal Squamous Cell Carcinoma
por: Gu, Yi-Min, et al.
Publicado: (2022)

Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma
por: Loc, Nguyen Vo Vinh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_readm6shobhbu0l25jsuji7gq0